- Home
- IGMS vs PNI Comparison
IGMS vs PNI Comparison
Compare IGMS & PNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- PNI
- Stock Information
- Founded
- IGMS 1993
- PNI 2002
- Country
- IGMS United States
- PNI United States
- Employees
- IGMS N/A
- PNI N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- PNI Trusts Except Educational Religious and Charitable
- Sector
- IGMS Health Care
- PNI Finance
- Exchange
- IGMS Nasdaq
- PNI Nasdaq
- Market Cap
- IGMS 82.1M
- PNI 82.7M
- IPO Year
- IGMS 2019
- PNI N/A
- Fundamental
- Price
- IGMS $1.38
- PNI $7.38
- Analyst Decision
- IGMS Hold
- PNI
- Analyst Count
- IGMS 8
- PNI 0
- Target Price
- IGMS $6.14
- PNI N/A
- AVG Volume (30 Days)
- IGMS 368.0K
- PNI 26.4K
- Earning Date
- IGMS 03-06-2025
- PNI 01-01-0001
- Dividend Yield
- IGMS N/A
- PNI 4.76%
- EPS Growth
- IGMS N/A
- PNI N/A
- EPS
- IGMS N/A
- PNI N/A
- Revenue
- IGMS $2,918,000.00
- PNI N/A
- Revenue This Year
- IGMS $26.85
- PNI N/A
- Revenue Next Year
- IGMS $125.17
- PNI N/A
- P/E Ratio
- IGMS N/A
- PNI N/A
- Revenue Growth
- IGMS 57.64
- PNI N/A
- 52 Week Low
- IGMS $1.26
- PNI $6.03
- 52 Week High
- IGMS $22.50
- PNI $7.89
- Technical
- Relative Strength Index (RSI)
- IGMS 26.21
- PNI 62.02
- Support Level
- IGMS $1.26
- PNI $7.25
- Resistance Level
- IGMS $1.54
- PNI $7.32
- Average True Range (ATR)
- IGMS 0.13
- PNI 0.08
- MACD
- IGMS 0.22
- PNI 0.01
- Stochastic Oscillator
- IGMS 29.27
- PNI 95.00
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.